ClassID:

110398

C12N2740/16033 - CPC Classification

Classification description:

Reverse transcribing RNA viruses; Details; Retroviridae; Human Immunodeficiency Virus, HIV Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Recent Application in this class:
#1
20250102520
2025-03-27

SIMULTANEOUS DETECTION OF ANTIGENS AND ANTIGEN SPECIFIC ANTIBODIES IN A GUINEA PIG MODEL SYSTEM

#2
20240317809
2024-09-26

Engineered Antimicrobial Peptides and Usage Thereof

#3
20220249653
2022-08-11

COMPOSITIONS AND METHODS FOR DETECTING HIV LATENCY, TREATING HIV INFECTION, AND REVERSING HIV LATENCY

#4
20210275592
2021-09-09

Immune cells with DNMT3A gene modifications and methods related thereto

#5
20210238252
2021-08-05

HIV antibody derivatives with dual antiviral and immunomodulatory activities from CD4 and GP41

#6
20210198320
2021-07-01

Cell-penetrating compstatin analogs and uses thereof

#7
20200377951
2020-12-03

FRATAXIN-SENSITIVE MARKERS FOR DETERMINING EFFECTIVENESS OF FRATAXIN REPLACEMENT THERAPY

#8
20190352357
2019-11-21

Helix-grafted proteins as inhibitors of disease-relevant protein-protein interactions

#9
20190337992
2019-11-07

Use of a HIV derived accessory protein for the reactivation of latent HIV

#10
20190248846
2019-08-15

MITOCHONDRIAL PROTEINS CONSTRUCTS AND USES THEREOF

#11
20190248839
2019-08-15

Cell-penetrating compstatin analogs and uses thereof

#12
20190202888
2019-07-04

Peptides having effects of preventing or treating central nervous system diseases and pharmaceutical compositions for preventing or treating central nervous system diseases containing same as active ingredient

#13
20180318350
2018-11-08

Immune cells with DNMT3A gene modifications and methods related thereto

#14
20180258142
2018-09-13

Methods for Optimizing CATS Immunotherapeutics into Humanized Derivatives with Reduced Autoreactivity, Reduced Toxicity and Enhanced Long-Term Efficacy

#15
20180016305
2018-01-18

DAGRS: directed antigonists to cancer cell growth signals

#16
20170296601
2017-10-19

Compositions and Methods for Treating an Immunodeficiency Virus Infection

#17
20170239325
2017-08-24

Autologous HIV-1 proteins for the treatment of latent HIV-1 infection

#18
20170087246
2017-03-30

Modular antigen transportation molecules and uses thereof in animals

#19
20170044218
2017-02-16

Use of a HIV derived accessory protein for the reactivation of latent HIV

#20
20170014479
2017-01-19

Therapeutic applications of Smad7

#21
20170014474
2017-01-19

Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4

#22
20160354462
2016-12-08

Vaccine and therapeutic delivery system

#23
20160250281
2016-09-01

Methods of treating obesity by administering a TAT peptide

#24
20160243169
2016-08-25

DUAL VECTOR FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS

#25
20160215022
2016-07-28

Cell-penetrating compstatin analogs and uses thereof

#26
20160206689
2016-07-21

Autologous HIV-1 proteins for the treatment of latent HIV-1 infection

#27
20160152676
2016-06-02

Helix-grafted proteins as inhibitors of disease-relevant protein-protein interactions

#28
20160083481
2016-03-24

Fusion proteins and immunoconjugates and uses thereof which are specific for glycophorin A

#29
20160075745
2016-03-17

Mitochondrial proteins constructs and uses thereof

#30
20160060302
2016-03-03

Expression of HIV inhibitors by Mesenchymal stem cells

#31
20160045591
2016-02-18

Vaccine and therapeutic delivery system

#32
20150306174
2015-10-29

Stabilized trimeric HIV-1 GP41 fusion inhibitor polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif

#33
20150290287
2015-10-15

Therapeutic applications of SMAD7

#34
20150175666
2015-06-25

PEPTIDES DERIVED FROM HIV GP41 FOR TREATING T-CELL MEDIATED PATHOLOGIES

#35
20150159171
2015-06-11

Vector for the selective silencing of a gene in astrocytes

#36
20150133384
2015-05-14

C-terminal fragments of glucagon-like peptide-1 (GLP-1)

#37
20150111836
2015-04-23

CELLULAR APOBEC3 PROTEINS AND MODULATORS THEREOF FOR REGULATING DNA REPAIR PROCESSES AND TREATING PROLIFERATIVE DISEASES

#38
20150111814
2015-04-23

Compositions for promoting HIV-1 virolysis and methods using same

#39
20140329757
2014-11-06

Tubulin-interacting protein, caltubin, promotes axonal growth

#40
20140121170
2014-05-01

Compositions and methods for treating AIDS or cancer by inhibiting the secretion of microparticles

#41
20140112936
2014-04-24

Antigenic polypeptides comprising pre-hairpin intermediate conformations of HIV-1 GP41

#42
20130095131
2013-04-18

Vaccine and therapeutic delivery system

#43
20130018003
2013-01-17

Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles

#44
20130018002
2013-01-17

Compositions and methods for treating cancer by inhibiting the secretion of microparticles

#45
20120201794
2012-08-09

DUAL VECTOR FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS

#46
20120093787
2012-04-19

Methods and compositions for inhibiting viral entry into cells

#47
20110274747
2011-11-10

C-terminal fragments of glucagon-like peptide-1 (GLP-1)

#48
20100317566
2010-12-16

Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles

#49
20100204120
2010-08-12

Stabilized trimeric HIV-1 gp41 fusion polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif

#50
20100074904
2010-03-25

Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4

#51
20090099533
2009-04-16

Virus derived antimicrobial peptides

#52
15503005
2019-02-05

Chimeric vector and preparation method and use thereof